Quinnova Pharmaceuticals, founded with a mission to innovate in the field of dermatology, focuses on developing and commercializing prescription drug products utilizing advanced dermal drug delivery platforms. The company offers a range of products including HYDRO 40 foam for dry skin treatment, Tersi foam for seborrheic dermatitis and tinea versicolor, and the Rinnovi nail system for treating various nail conditions. Quinnova's market focus is on providing effective dermatological solutions to improve patient outcomes.

Notable figures affiliated with Quinnova Pharmaceuticals include experienced dermatologists and pharmaceutical experts who contribute to its innovative product development. The company has achieved significant milestones, such as the successful commercialization of multiple dermal treatments that have been well-received in the medical community. Quinnova's impact lies in its ability to address unmet needs in dermatology through its specialized drug delivery systems, enhancing the quality of life for patients with skin and nail conditions.